A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy.

Autor: Stein-Thoeringer CK; Division of Microbiome and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Internal Medicine I, University Clinic Tuebingen, Tuebingen, Germany., Saini NY; Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX, USA. nsaini@mdanderson.org.; Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA. nsaini@mdanderson.org., Zamir E; Division of Microbiome and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany., Blumenberg V; Medizinische Klinik III, LMU Klinikum, Munich, Germany.; Laboratory for Translational Cancer Immunology, Gene Center of the LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK) and Bavarian Center for Cancer Research (BZKF), partner site Munich, Munich, Germany., Schubert ML; Department of Hematology, Oncology and Rheumatology, University Clinic Heidelberg, Heidelberg, Germany., Mor U; Systems Immunology Department, Weizmann Institute of Science, Rehovot, Israel., Fante MA; Department of Internal Medicine III, University Clinic Regensburg, Regensburg, Germany., Schmidt S; Division of Microbiome and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany., Hayase E; Department of Genomic Medicine, MD Anderson Cancer Center, Houston, TX, USA., Hayase T; Department of Genomic Medicine, MD Anderson Cancer Center, Houston, TX, USA., Rohrbach R; Division of Microbiome and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany., Chang CC; Department of Genomic Medicine, MD Anderson Cancer Center, Houston, TX, USA., McDaniel L; Department of Genomic Medicine, MD Anderson Cancer Center, Houston, TX, USA., Flores I; Department of Genomic Medicine, MD Anderson Cancer Center, Houston, TX, USA., Gaiser R; Division of Microbiome and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany., Edinger M; German Cancer Consortium (DKTK) and Bavarian Center for Cancer Research (BZKF), partner site Munich, Munich, Germany.; Department of Internal Medicine III, University Clinic Regensburg, Regensburg, Germany.; Leibnitz Institut für Immuntherapie (LIT), Regensburg, Germany., Wolff D; German Cancer Consortium (DKTK) and Bavarian Center for Cancer Research (BZKF), partner site Munich, Munich, Germany.; Department of Internal Medicine III, University Clinic Regensburg, Regensburg, Germany.; Leibnitz Institut für Immuntherapie (LIT), Regensburg, Germany., Heidenreich M; German Cancer Consortium (DKTK) and Bavarian Center for Cancer Research (BZKF), partner site Munich, Munich, Germany.; Leibnitz Institut für Immuntherapie (LIT), Regensburg, Germany., Strati P; Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA., Nair R; Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA., Chihara D; Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA., Fayad LE; Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA., Ahmed S; Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA., Iyer SP; Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA., Steiner RE; Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA., Jain P; Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA., Nastoupil LJ; Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA., Westin J; Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA., Arora R; Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA., Wang ML; Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA., Turner J; Department of Clinical Science, Moffitt Cancer Center, Tampa, FL, USA., Menges M; Department of Clinical Science, Moffitt Cancer Center, Tampa, FL, USA., Hidalgo-Vargas M; Department of Clinical Science, Moffitt Cancer Center, Tampa, FL, USA., Reid K; Department of Clinical Science, Moffitt Cancer Center, Tampa, FL, USA., Dreger P; Department of Hematology, Oncology and Rheumatology, University Clinic Heidelberg, Heidelberg, Germany., Schmitt A; Department of Hematology, Oncology and Rheumatology, University Clinic Heidelberg, Heidelberg, Germany., Müller-Tidow C; Department of Hematology, Oncology and Rheumatology, University Clinic Heidelberg, Heidelberg, Germany., Locke FL; Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center and Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, FL, USA., Davila ML; Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center and Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, FL, USA., Champlin RE; Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX, USA., Flowers CR; Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA., Shpall EJ; Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX, USA., Poeck H; German Cancer Consortium (DKTK) and Bavarian Center for Cancer Research (BZKF), partner site Munich, Munich, Germany.; Department of Internal Medicine III, University Clinic Regensburg, Regensburg, Germany.; Leibnitz Institut für Immuntherapie (LIT), Regensburg, Germany., Neelapu SS; Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA., Schmitt M; Department of Hematology, Oncology and Rheumatology, University Clinic Heidelberg, Heidelberg, Germany., Subklewe M; Medizinische Klinik III, LMU Klinikum, Munich, Germany.; Laboratory for Translational Cancer Immunology, Gene Center of the LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK) and Bavarian Center for Cancer Research (BZKF), partner site Munich, Munich, Germany., Jain MD; Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center and Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, FL, USA. michael.jain@moffitt.org., Jenq RR; Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX, USA. rrjenq@mdanderson.org.; Department of Genomic Medicine, MD Anderson Cancer Center, Houston, TX, USA. rrjenq@mdanderson.org.; CPRIT Scholar in Cancer Research, University of Texas, Houston, USA. rrjenq@mdanderson.org., Elinav E; Division of Microbiome and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany. e.elinav@dkfz-heidelberg.de.; Systems Immunology Department, Weizmann Institute of Science, Rehovot, Israel. e.elinav@dkfz-heidelberg.de.

Publikováno v: Nature medicine [Nat Med] 2023 Apr; Vol. 29 (4), pp. 906-916. Date of Electronic Publication: 2023 Mar 13.

Correction to: Severe Dysbiosis and Specific Haemophilus and Neisseria Signatures as Hallmarks of the Oropharyngeal Microbiome in Critically Ill Coronavirus Disease 2019 (COVID-19) Patients.

Autor: de Castilhos J; German Cancer Research Center (DKFZ), Research Division Microbiome and Cancer, Heidelberg, Germany.; Vale do Rio dos Sinos University (UNISINOS), Sao Leopoldo, Brazil., Zamir E; German Cancer Research Center (DKFZ), Research Division Microbiome and Cancer, Heidelberg, Germany., Hippchen T; Department of Gastroenterology and Infectious Diseases, University Clinic Heidelberg, Heidelberg, Germany., Rohrbach R; German Cancer Research Center (DKFZ), Research Division Microbiome and Cancer, Heidelberg, Germany., Schmidt S; German Cancer Research Center (DKFZ), Research Division Microbiome and Cancer, Heidelberg, Germany., Hengler S; German Cancer Research Center (DKFZ), Research Division Microbiome and Cancer, Heidelberg, Germany., Schumacher H; German Cancer Research Center (DKFZ), Research Division Microbiome and Cancer, Heidelberg, Germany., Neubauer M; Department of Medicine II, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Kunz S; Department of Internal Medicine III, University Clinic Regensburg, Regensburg, Germany., Müller-Esch T; Department of Internal Medicine III, University Clinic Regensburg, Regensburg, Germany., Hiergeist A; Institute of Clinical Microbiology and Hygiene, University Clinic Regensburg, Regensburg, Germany., Gessner A; Institute of Clinical Microbiology and Hygiene, University Clinic Regensburg, Regensburg, Germany., Khalid D; Department of Virology, University Clinic Heidelberg, Heidelberg, Germany., Gaiser R; German Cancer Research Center (DKFZ), Research Division Microbiome and Cancer, Heidelberg, Germany., Cullin N; German Cancer Research Center (DKFZ), Research Division Microbiome and Cancer, Heidelberg, Germany., Papagiannarou SM; German Cancer Research Center (DKFZ), Research Division Microbiome and Cancer, Heidelberg, Germany., Beuthien-Baumann B; German Cancer Research Center (DKFZ), Research Division Radiology, Heidelberg, Germany., Krämer A; German Cancer Research Center (DKFZ), Research Division Molecular Hematology/Oncology, Heidelberg, Germany., Bartenschlager R; Department of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany.; German Cancer Research Center (DKFZ), Research Division Virus-associated Carcinogenesis, Heidelberg., Jäger D; National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany., Müller M; Thoraxklinik and Translational Lung Research Center, Heidelberg University, Heidelberg, Germany., Herth F; Thoraxklinik and Translational Lung Research Center, Heidelberg University, Heidelberg, Germany., Duerschmied D; Department of Internal Medicine III, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Schneider J; Department of Internal Medicine II, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany., Schmid RM; Department of Internal Medicine II, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany., Eberhardt JF; Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Frankfurt, Germany., Khodamoradi Y; Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Frankfurt, Germany., Vehreschild MJGT; Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Frankfurt, Germany.; German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany., Teufel A; Department of Medicine II, Section of Hepatology, University Medical Center Mannheim, University of Heidelberg, Mannheim, and Center for Preventive Medicine and Digital Health Baden-Württemberg, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany., Ebert MP; Department of Medicine II, Section of Hepatology, University Medical Center Mannheim, University of Heidelberg, Mannheim, and Center for Preventive Medicine and Digital Health Baden-Württemberg, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany., Hau P; Wilhelm Sander-NeuroOncology Unit and Department of Neurology, University Clinic Regensburg, Regensburg, Germany., Salzberger B; Department of Infectious Disease, University Clinic Regensburg, Regensburg, Germany., Schnitzler P; Department of Virology, University Clinic Heidelberg, Heidelberg, Germany., Poeck H; Department of Internal Medicine III, University Clinic Regensburg, Regensburg, Germany.; National Center for Tumor Diseases (NCT) WERA., Elinav E; German Cancer Research Center (DKFZ), Research Division Microbiome and Cancer, Heidelberg, Germany.; Weizmann Institute of Science, Rehovot, Israel., Merle U; Department of Gastroenterology and Infectious Diseases, University Clinic Heidelberg, Heidelberg, Germany., Stein-Thoeringer CK; German Cancer Research Center (DKFZ), Research Division Microbiome and Cancer, Heidelberg, Germany.; National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany.

Publikováno v: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2022 Aug 24; Vol. 75 (1), pp. 185.

The Potential Role of the Intestinal Micromilieu and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy.

Autor: Schubert ML; Klinik fuer Haematologie, Onkologie und Rheumatologie, Universitätsklinikum Heidelberg, Heidelberg, Germany., Rohrbach R; Research Division Microbiome and Cancer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany., Schmitt M; Klinik fuer Haematologie, Onkologie und Rheumatologie, Universitätsklinikum Heidelberg, Heidelberg, Germany., Stein-Thoeringer CK; Research Division Microbiome and Cancer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany.; Klinik fuer Medizinische Onkologie, Nationales Centrum für Tumorerkrankungen (NCT), Heidelberg, Germany.

Publikováno v: Frontiers in immunology [Front Immunol] 2021 May 31; Vol. 12, pp. 670286. Date of Electronic Publication: 2021 May 31 (Print Publication: 2021).

Design and Preliminary Evaluation of Automated Sweetpotato Sorting Mechanisms.

Autor: Xu, Jiajun¹ (AUTHOR), Lu, Yuzhen¹ (AUTHOR) luyuzhen@msu.edu

Publikováno v: AgriEngineering. Sep2024, Vol. 6 Issue 3, p3058-3069. 12p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.